This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
WEBER, DONNA M
| Item Type | Name |
|
Academic Article
|
Novel agents for relapsed and/or refractory multiple myeloma.
|
|
Academic Article
|
Advances in treatment for relapses and refractory multiple myeloma.
|
|
Academic Article
|
Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.
|
|
Academic Article
|
Multiple myeloma, version 1.2013.
|
|
Academic Article
|
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.
|
|
Academic Article
|
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
|
|
Academic Article
|
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.
|
|
Academic Article
|
Value of novel agents and intensive therapy for patients with multiple myeloma.
|
|
Academic Article
|
Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
|
|
Academic Article
|
Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial.
|
|
Academic Article
|
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
|
|
Academic Article
|
Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome.
|
|
Concept
|
Bortezomib
|
|
Academic Article
|
Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
|
|
Academic Article
|
Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance.
|
|
Academic Article
|
KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma.
|